Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Sanofi at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Sanofi brings 10 presentations to ASH 2026 in New Orleans, and exhibits at Booth 2939. Its program centres on rilzabrutinib and fitusiran clinical trials across immune, blood and clotting conditions. Sanofi hosts exhibit-floor trial showcases on these studies and supports symposia on hemophilia and immune thrombocytopenia.

OrganizationASH 2026 Attendance
Sanofi
Paris, France
Large pharma
Global healthcare company developing medicines and vaccines, with teams in around 100 countries.
Booth
Exhibiting at Booth 2939
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies
Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects.
Myeloma
Symposium
Fri Dec 11
11:00am–2:00pm
Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice
Newly diagnosed multiple myeloma care in community clinics, using frailty assessment, dose adjustment to protect quality of life, and new drug formulations.
Myeloma
Symposium
Fri Dec 11
3:00pm–6:00pm
Hemophilia at the Crossroads: New Evidence for Individualized Care
Tailoring hemophilia prevention with factor replacement, factor-mimicking drugs, rebalancing agents, and gene therapy to protect joints and ease treatment burden.
Clotting
Symposium
Fri Dec 11
3:00pm–6:00pm
ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centered Care
Personalizing immune thrombocytopenia care beyond platelet counts, weighing new therapies alongside fatigue, cognition, heavy periods, and quality of life.
Clotting
Symposium
Fri Dec 11
3:00pm–6:00pm
Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice
Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies.
Symposium hosted by National Comprehensive Cancer Network and Decera Clinical Education
Myeloma
Symposium
Fri Dec 11
3:00pm–6:00pm
Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence
Tailoring four-drug frontline regimens for newly diagnosed myeloma using residual disease testing, transplant criteria, and new ways of giving treatment.
Symposium hosted by Answers in CME
Myeloma
Talk
Sun Dec 13
8:00am–9:00am

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Sanofi

Tell us what you sell and we’ll find the people at Sanofi most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction